Intraepithelial Neoplasia Clinical Trials

39 recruitingLast updated: May 11, 2026

There are 39 actively recruiting intraepithelial neoplasia clinical trials across 16 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 4. Top locations include Ningbo, Zhejiang, China, Shanghai, Shanghai Municipality, China, Milan, Italy. Updated daily from ClinicalTrials.gov.


Intraepithelial Neoplasia Trials at a Glance

39 actively recruiting trials for intraepithelial neoplasia are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Not Applicable with 14 trials, with the heaviest enrollment activity in Ningbo, Shanghai, and Milan. Lead sponsors running intraepithelial neoplasia studies include Changhai Hospital, Dana-Farber Cancer Institute, and European Institute of Oncology.

Browse intraepithelial neoplasia trials by phase

Treatments under study

About Intraepithelial Neoplasia Clinical Trials

Looking for clinical trials for Intraepithelial Neoplasia? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Intraepithelial Neoplasia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Intraepithelial Neoplasia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 39 trials

Recruiting
Phase 2

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

Cervical Intraepithelial Neoplasia Grade 2/3Human Papilloma Virus Infection Type 16
PapiVax Biotech, Inc.138 enrolled10 locationsNCT07454915
Recruiting
Phase 1

Lopinavir/Ritonavir in PLWH With High-Grade AIN

High-Grade Anal Intraepithelial Neoplasia
University of Wisconsin, Madison21 enrolled1 locationNCT05334004
Recruiting
Not Applicable

Digital Telecytology for Triage of HPV-Positive Women in Cameroon

Human Papillomavirus InfectionCervical Cancer Screening MethodsCervical Intraepithelial Neoplasia Grade 2 (CIN2)
University Hospital, Geneva1,800 enrolled2 locationsNCT07550010
Recruiting

Endometrial Cancer Vaginal Fluid Specimen Collection Study

Endometrial CancerEndometrial Intraepithelial NeoplasiaAtypical Endometrial Hyperplasia+2 more
Exact Sciences Corporation4,200 enrolled1 locationNCT07544680
Recruiting
Not Applicable

Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer

I) Atypical Squamous Cells of Undetermined Significance (ASC-US)II) Atypical Glandular Cells of Uncertain Significance (AGUS)III) Cervical Intraepithelial Neoplasia (CIN), CIN-1, CIN-2, CIN-3+3 more
Timser SAPI de CV558 enrolled1 locationNCT07480902
Recruiting
Not Applicable

Point of Care - Triage and Treatment for Cervical Pre-cancer

Cervical Intraepithelial NeoplasiaHuman Papillomavirus InfectionCervical Precancer
Basic Health International, Inc.5,000 enrolled1 locationNCT07461818
Recruiting
Phase 2

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Cervical Intraepithelial NeoplasiaCervical Squamous Cell Carcinoma In SituCervical Squamous Intraepithelial Neoplasia 2
Jonsson Comprehensive Cancer Center25 enrolled1 locationNCT04712851
Recruiting
Not Applicable

A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV.

HPVCIN - Cervical Intraepithelial NeoplasiaCIN 1+2 more
Papillex Inc.60 enrolled1 locationNCT06979180
Recruiting
Phase 4

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III)Human Papillomavirus (HPV) InfectionsHigh-risk HPV+1 more
Miquel Angel Pavon Ribas69 enrolled1 locationNCT05334706
Recruiting
Not Applicable

Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer

Uterine Cervical NeoplasmsCervical CancersCervical Intraepithelial Neoplasia+1 more
DL Analytics10,000 enrolled1 locationNCT06815939
Recruiting
Phase 2

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

HPV-Related CarcinomaHPV InfectionGenital Wart+1 more
Shanghai Bovax Biotechnology Co., Ltd.330 enrolled1 locationNCT06756269
Recruiting
Not Applicable

Human Papillomavirus Self-sampling for Enhancing Cervical Screening During the War in Ukraine

Cervical CancerCervical Cancer ScreeningCervical Intraepithelial Neoplasia+1 more
Karolinska Institutet1,000 enrolled1 locationNCT07275333
Recruiting
Phase 4

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Breast NeoplasmsColorectal NeoplasmsHead and Neck Neoplasms+1 more
Rutgers, The State University of New Jersey100 enrolled12 locationsNCT07158164
Recruiting
Phase 1

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Cervical Intraepithelial NeoplasiaInvasive Cervical Cancer
Lindsay Ferguson, MD24 enrolled1 locationNCT06191133
Recruiting
Not Applicable

Deciphering Mechanisms Underlying Cancer Immunogenicity

Ovarian CancerCervical CancerHead and Neck Cancer+4 more
Institut Claudius Regaud1,100 enrolled3 locationsNCT03958240
Recruiting
Phase 1

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

Human Papillomavirus Type 16Cervical Intraepithelial Neoplasia Grade IICervical Intraepithelial Neoplasia, Grade III
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins48 enrolled2 locationsNCT04131413
Recruiting
Phase 2

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Vulvar DiseasesHPV InfectionHigh Grade Intraepithelial Neoplasia+10 more
Frantz Viral Therapeutics, LLC27 enrolled5 locationsNCT06075264
Recruiting

Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

Pancreatic CancerPDAC - Pancreatic Ductal AdenocarcinomaIntraductal Papillary Mucinous Neoplasm+2 more
Changhai Hospital400,000 enrolled5 locationsNCT07117045
Recruiting
Not Applicable

Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia

ObesityEndometrial CarcinomaEndometrial Intraepithelial Neoplasia+2 more
Dana-Farber Cancer Institute30 enrolled2 locationsNCT04839614
Recruiting

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Lung CancerCancer RiskCancer Predisposition Syndrome+28 more
Dana-Farber Cancer Institute5,000 enrolled1 locationNCT05463796